Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Plunkett Research, Ltd.
$99.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Charles River Laboratories International Inc Reaffirms FY 2013 Guidance


Wednesday, 31 Jul 2013 04:25pm EDT 

Charles River Laboratories International announced that it is reaffirming its sales and non-GAAP earnings per share (EPS) guidance for fiscal 2013. For fiscal 2013, the Company expects net sales growth, reported in the range of 3.0%-5.0% (prior range 3.0%-5.0%), net sales growth, constant currency in the range of 4.0%-6.0% (prior range 4.0%-6.0%), GAAP EPS in the range of $2.40-$2.50 (prior range $2.45-$2.55) and Non-GAAP EPS in the range of $$2.80-$2.90 (prior range $2.80-$2.90). The Company reported revenue of $1.130 billion in fiscal 2012. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $1.171 billion and EPS of $2.82 for fiscal 2013. 

Company Quote